{"slideshow_credits": null, "snippet": "The final settlement is likely to be close to the $780 million that Amgen had set aside, with about $150 million being the criminal penalty, a person close to the inquiry said.", "abstract": "Biotechnology giant Amgen is expected to plead guilty to illegally marketing its drugs; payment will likely be close to the $780 million Amgen set aside in 2010 to prepare for 10 separate whistle-blower lawsuits.", "section_name": "Business Day", "print_page": "3", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2012/12/18/business/amgen-expected-to-plead-guilty-in-us-case.html", "lead_paragraph": "The final settlement is likely to be close to the $780 million that Amgen had set aside, with about $150 million being the criminal penalty, a person close to the inquiry said.", "headline": {"main": "Amgen Expected to Plead Guilty in U.S. Case", "print_headline": "Amgen Expected to Plead Guilty in U.S. Case"}, "_id": "50d0e65200315214fbb7ff82", "word_count": "508", "multimedia": [], "pub_date": "2012-12-18T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Amgen Inc", "name": "organizations", "is_major": "Y", "rank": "1"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Regulation and Deregulation of Industry", "name": "subject", "is_major": "N", "rank": "3"}], "blog": [], "subsection_name": null, "type_of_material": "News"}